Status:

COMPLETED

Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients

Lead Sponsor:

Sichuan Cancer Hospital and Research Institute

Collaborating Sponsors:

the Norman Bethune's "Research Wing Promotion"-Supporting Research Projects

Peking Union Medical College Hospital Talent Cultivation Program

Conditions:

Gynecological Tumor

Ovarian Cancer

Eligibility:

FEMALE

20-75 years

Phase:

PHASE3

Brief Summary

To determine the best method to prevent CINV caused by TC regimen in patients with gynecological malignant tumor. Paclitaxel-carboplatin (TC) is the most widely used regimen for gynecologic malignanc...

Detailed Description

The risk of vomiting caused by high-dose carboplatin is controversial, and there is currently no prevention of TC in patients with gynecological malignant tumors High-level evidence-based medical evid...

Eligibility Criteria

Inclusion

  • Eligibility criteria: histologically confirmed gynecologic malignancies (including newly diagnosed cases and recurrent cases without chemo- or radiotherapy within the past six months); age 20-75 years; ECOG performance status 0-2; scheduled to receive at least two cycles of paclitaxel (175 mg/m²) plus carboplatin (AUC 5-6) every 3 weeks; and adequate organ function (bilirubin and creatinine within normal range, ALT and AST \< 2× upper limit of normal).
  • Exclusion criteria: included prior chemotherapy, radiotherapy, or targeted therapy for the current recurrence; known brain metastases or history of brain tumors; history of gastrointestinal malignancy or major gastrointestinal surgery (except polypectomy or appendectomy); incomplete bowel obstruction; vestibular dysfunction; massive ascites (unless drained); concomitant opioid use; or diabetes mellitus.

Exclusion

    Key Trial Info

    Start Date :

    May 31 2024

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    July 4 2025

    Estimated Enrollment :

    143 Patients enrolled

    Trial Details

    Trial ID

    NCT06007586

    Start Date

    May 31 2024

    End Date

    July 4 2025

    Last Update

    December 4 2025

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Dengfeng Wang

    Chengdu, Sichua, China, 610041

    2

    Sichuan Cancer Hospital

    Chengdu, China